Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 172 matching drugs for STAT5B — including drugs targeting any of its 13 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib STAT5B Direct 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment STAT5B Direct 2
afatinib, dasatinib, palbociclib, everolimus, olaparib STAT5B Direct 1
bevacizumab, dasatinib, placebo STAT5B Direct 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride STAT5B Direct 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method STAT5B Direct 1
dasatinib, laboratory biomarker analysis, physiologic testing STAT5B Direct 1
dasatinib, mfolfox6 STAT5B Direct 1
dasatinib, pharmacological study STAT5B Direct 1
dasatinib, temozolomide, placebo, radiation therapy STAT5B Direct 1
sunitinib PDGFRB SSL via PDGFRB yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRB SSL via PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRB SSL via PDGFRB 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK14 SSL via MAPK14 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRB SSL via PDGFRB 3
afatinib ERBB2 SSL via ERBB2 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment MAPK14 SSL via MAPK14 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PDGFRB SSL via PDGFRB 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PDGFRB SSL via PDGFRB 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
lapatinib ERBB2 SSL via ERBB2 yes 2
nintedanib PDGFRB SSL via PDGFRB yes 2
nintedanib, pembrolizumab PDGFRB SSL via PDGFRB 2
pazopanib PDGFRB SSL via PDGFRB yes 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
regorafenib PDGFRB SSL via PDGFRB yes 2
regorafenib, laboratory biomarker analysis PDGFRB SSL via PDGFRB 2
sorafenib, administered orally, ct/mri PDGFRB SSL via PDGFRB 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MAPK14 SSL via MAPK14 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PDGFRB SSL via PDGFRB 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
atezolizumab, tivozanib PDGFRB SSL via PDGFRB 1
bevacizumab, dasatinib, placebo MAPK14 SSL via MAPK14 1
bevacizumab, dasatinib, placebo PDGFRB SSL via PDGFRB 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib PDGFRB SSL via PDGFRB 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging PDGFRB SSL via PDGFRB 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab ERBB2 SSL via ERBB2 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography PDGFRB SSL via PDGFRB 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab PDGFRB SSL via PDGFRB 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab ERBB2 SSL via ERBB2 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab ERBB2 SSL via ERBB2 1
cetuximab, trastuzumab ERBB2 SSL via ERBB2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy ERBB2 SSL via ERBB2 1
cisplatin, pemetrexed disodium, sorafenib PDGFRB SSL via PDGFRB 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride MAPK14 SSL via MAPK14 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride PDGFRB SSL via PDGFRB 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method MAPK14 SSL via MAPK14 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method PDGFRB SSL via PDGFRB 1
dasatinib, laboratory biomarker analysis, physiologic testing MAPK14 SSL via MAPK14 1
dasatinib, laboratory biomarker analysis, physiologic testing PDGFRB SSL via PDGFRB 1
dasatinib, mfolfox6 MAPK14 SSL via MAPK14 1
dasatinib, mfolfox6 PDGFRB SSL via PDGFRB 1
dasatinib, pharmacological study MAPK14 SSL via MAPK14 1
dasatinib, pharmacological study PDGFRB SSL via PDGFRB 1
dasatinib, temozolomide, placebo, radiation therapy MAPK14 SSL via MAPK14 1
dasatinib, temozolomide, placebo, radiation therapy PDGFRB SSL via PDGFRB 1
db-1310, trastuzumab, osimertinib ERBB2 SSL via ERBB2 1
disitamab vedotin, tucatinib ERBB2 SSL via ERBB2 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab ERBB2 SSL via ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab ERBB2 SSL via ERBB2 1
entrectinib JAK2 SSL via JAK2 yes 1
eras-007, encorafenib, cetuximab, palbociclib MAPK8 SSL via MAPK8 1
erdafitinib PDGFRB SSL via PDGFRB 1
everolimus, sorafenib PDGFRB SSL via PDGFRB 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel ERBB2 SSL via ERBB2 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig ERBB2 SSL via ERBB2 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB1 SSL via NFKB1 1
gemcitabine, erlotinib, sorafenib PDGFRB SSL via PDGFRB 1
gemcitabine, oxaliplatin, imatinib PDGFRB SSL via PDGFRB 1
gemcitabine, placebo, sorafenib PDGFRB SSL via PDGFRB 1
gemcitabine, sorafenib, radiotherapy PDGFRB SSL via PDGFRB 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff PDGFRB SSL via PDGFRB 1
gemcitabine, sunitinib PDGFRB SSL via PDGFRB 1
imatinib, irinotecan, carboplatin PDGFRB SSL via PDGFRB 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery ERBB2 SSL via ERBB2 1
lapatinib, chemoradiation, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin ERBB2 SSL via ERBB2 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil PDGFRB SSL via PDGFRB 1
lmb-100, tofacitinib, mesothelin expression JAK2 SSL via JAK2 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab ERBB2 SSL via ERBB2 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab ERBB2 SSL via ERBB2 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab ERBB2 SSL via ERBB2 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.